Arcus Biosciences, Inc. (RCUS) FY2026 Q2 P&L / Income Statement
2026-04-01 to 2026-06-30
Revenue by Product and Service
2026-04-01 to 2026-06-30
Swipe to see the full flow
Chart details
Arcus Biosciences, Inc. (RCUS) FY2026 Q2 P&L / Income Statement
Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 41,000,000 US dollars
- Total operating expenses
- 137,000,000 US dollars
- Loss from operations
- negative 96,000,000 US dollars
- Total non-operating income, net
- 5,000,000 US dollars
- Income (loss) before income taxes
- negative 91,000,000 US dollars
- Income tax expense
- 0 US dollars
- Net income (loss)
- negative 91,000,000 US dollars
- License and development services
- 16,000,000 US dollars
- Other collaboration
- 25,000,000 US dollars
- Total operating expenses
- 137,000,000 US dollars
Chart connections
- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Operating margin
−234.1%
Operating profit / revenue
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!